Targeted therapy in HER2-positive breast cancer
نویسندگان
چکیده
منابع مشابه
Targeted therapy for HER2 positive breast cancer
INTRODUCTION Breast cancer is the second most common cause of death for women behind lung cancer and the most common cause of cancer deaths for women aged 45-55 years old (CDC.gov 2012). Although there continue to be enormously large numbers of disease incidence, deaths have been declining due to the disease with two hallmark time frames. The first occurred during the mid to late 1980's when ho...
متن کاملPOINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.
The primary goals when treating patients with metastatic breast cancer are to improve both duration and quality of life. With cytotoxic chemotherapy, this is typically achieved by using single agents sequentially (rather than combination regimens), switching therapies in the face of disease progression or prohibitive toxicity. This approach is supported by clinical trial data showing that chemo...
متن کاملTargeted Therapy of HER2-Negative Breast Cancer.
Personalized and targeted treatments are the most discussed topics in oncology. However, how much personalized medicine is standard of care nowadays and how much is part of our hope for a better future? So far, only a few targeted therapies are available in daily practice for the treatment of human epidermal growth factor receptor 2 (HER2)-negative breast cancer. And even for these few targeted...
متن کاملNeoadjuvant Therapy for HER2-positive Breast Cancer.
In HER2-positive early breast cancer, neoadjuvant treatment with a combination of sequential chemotherapy and HER2-targeted therapy is currently the standard of care. This is followed by breast surgery, radiotherapy (if indicated), completion of 12 months of HER2-directed therapy, and - depending on the tumor biology - endocrine adjuvant therapy, and ultimately follow up. 10-year survival rates...
متن کاملTargeted Therapies in HER2-Positive Breast Cancer - a Systematic Review.
About 20% of all breast cancer patients have a human epidermal growth factor receptor 2 (HER2)-positive breast tumor. This entity underwent an impressive change in prognosis, with notable improvement of progression-free survival and overall survival. Due to more aggressive tumors and no specific therapy, HER2 overexpression was historically seen as a negative prognostic marker, with worse progn...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biomedical Reports
سال: 2013
ISSN: 2049-9434,2049-9442
DOI: 10.3892/br.2013.95